Levi & Korsinsky, LLP announces that a CRMD class action lawsuit has been filed on behalf of investors who purchased CorMedix Inc. (CRMD) securities between July 8, 2020, and May 13, 2021. For more on the CRMD Lawsuit please contact us today.

According to the CorMedix lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to DefenCath’s manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) In light of the foregoing deficiencies, the Food and Drug Administration (“FDA”) was unlikely to approve the DefenCath new drug application (“NDA”) for catheter-related bloodstream infections (“CRBSIs”) in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath’s manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

TO LEARN MORE ABOUT THE CRMD CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in CorMedix you have until September 20, 2021, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com